Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

Wedbush reissued their outperform rating on shares of Gossamer Bio (NASDAQ:GOSS – Free Report) in a report released on Friday ...

Gossamer Bio ( ($GOSS) ) has released its Q4 earnings. Here is a breakdown of the information Gossamer Bio presented to its investors. Gossamer ...

EDT Gossamer Bio (GOSS) reports Q4 revenue $9.4M, consensus $7.0MLight Up your Portfolio with Spark:Easily identify stocks' risks and ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

Cash, cash equivalents and marketable securities as of December 31, 2024, were $294.5 million. As a result, we expect our ...

On a per-share basis, the San Diego-based company said it had a loss of 15 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

Explore Gossamer Bio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for GOSS. Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says ...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...

Oracle and Disney are among the stocks that fell into undervalued territory. We sell different types of products and services to both investment professionals and individual investors. These ...